The WHOOP closeout letter just redrew the wellness device line
FDA closed its warning letter over WHOOP's blood pressure feature, and the January wellness guidance behind that reversal tells wellness brands exactly where the device line now sits.
Last month the FDA quietly closed out the warning letter it sent WHOOP over its Blood Pressure Insights feature, posting a closeout letter dated June 17 and confirming it will not enforce medical device requirements against the modified feature. If your product measures, estimates, or infers anything physiological, this is the most useful regulatory document of the year, because the fight that produced it redrew the line between a general wellness product and a regulated medical device.
The short history matters. In July 2025 the FDA told WHOOP that blood pressure estimates are inherently associated with diagnosing hypertension, full stop, so the feature was a device requiring clearance. WHOOP refused to pull it. Then in January 2026 the agency updated its General Wellness guidance and changed its own answer: a noninvasive product that senses or infers physiologic parameters, including blood pressure, can qualify as a general wellness product if it is intended solely for wellness use. WHOOP adjusted the feature, notably the dial boundaries, so it no longer looked like it was classifying blood pressure in a clinical way, and the FDA stood down.
Here is the operational translation. The line is no longer drawn at what your sensor measures. It is drawn at what your product says. Intended use is judged objectively, from your labeling, your app copy, your marketing, your influencer briefs, and your founder’s podcast appearances, not from what you privately meant. The guidance sets out conditions that read like a checklist for your marketing team: no diagnostic or treatment claims, no claims of substituting for a cleared device, no outputs that guide clinical management, and no values that mimic clinical measurements unless validated. You can even tell users to talk to a doctor when a reading falls outside normal ranges, as long as the notification names no disease and characterizes nothing as abnormal or pathological. WHOOP’s fix was not an engineering change to the sensor. It was a change to how the number was framed on screen.
Two cautions before anyone celebrates. First, the same objective intended use standard that saved WHOOP will sink a brand whose growth team writes “know if you’re heading toward hypertension” in a paid ad. One claim surface can convert your whole product into an unapproved device. Second, escaping FDA device regulation does not mean escaping regulation. The FTC still expects reasonable security and substantiated claims, state health privacy laws like Washington’s still reach wellness data, and if your product integrates with providers you may be a HIPAA business associate anyway.
The concrete move for this quarter: write a one-page intended use statement for each physiologic feature you offer, then audit every claim surface against it. App store listing, onboarding screens, push notifications, ad creative, affiliate and influencer talking points, and support macros. Anywhere a disease name, a clinical threshold, or the word “detect” appears next to a physiologic number, fix it now, while the fix is still copy and not a premarket submission.